ClinicalTrials.gg
CompletedNCT03459040Updated Jul 12, 2021Results posted

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

A Phase 2 interventional study of Alpha 1-Antitrypsin in Graft-versus-host-disease and GVHD, sponsored by John Levine. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by John Levine · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
192nd of 389
30 · median 30
Started
2018
with 14 others
Phase 2
164 of 454
15 open now
Registered
343rd of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 192nd largest by enrollment of the 389 interventional ones that give a count, is one of 15 that started in 2018, is one of 164 in phase 2, and was the 343rd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

Bone marrow transplant (BMT) patients can develop graft-versus-host disease (GVHD), a serious and potentially fatal complication. The researchers have developed a blood test to identify patients most at risk for developing severe GVHD. Patients who consent to this study will have their blood tested up to two times after BMT to determine if they are at high risk for severe GVHD. The tests will be performed one week and two weeks after BMT. Patients who are high risk will be treated with a drug called alpha-1-antitrypsin (AAT) to see if it prevents the development of severe GVHD. Patients will receive 16 doses of AAT through a catheter placed into a blood vessel over eight weeks. AAT will be given either in the hospital or the outpatient clinic two times per week. Patients will be followed for the development of severe GVHD for up to four months from the BMT and will continue to be followed at routine clinic visits for up to one year after BMT.

03

Conditions studied

  • Graft-versus-host-disease
  • GVHD

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High risk prediction score as determined by the Mount Sinai Acute International Consortium (MAGIC) algorithm at either day 7 or day 14 post Hematopoietic cell transplant (HCT).
  • Any donor type (e.g., related, unrelated) or stem cell source (bone marrow, peripheral blood, cord blood).
  • Donor and recipient match each other for at least 7/8 HLA-loci (HLA-A, B, C, and DR)
  • Any conditioning regimen (non-myeloablative, myeloablative, or reduced intensity) is acceptable.
  • GVHD prophylaxis must include a calcineurin inhibitor combined with methotrexate or mycophenolate.
  • The use of serotherapy to prevent GVHD (e.g., antithymocyte globulin) prior to day 3 post-HCT is permitted
  • Direct must be \<2 mg/dL unless the elevation is known to be due to Gilbert syndrome within 3 days prior to enrollment.
  • /SGPT and AST/SGOT must be \<5 x the within 3 days prior to enrollment.
  • Signed and dated written obtained from patient or legal representative.

Exclusion criteria

Exclusion Criteria:

  • Patients who develop acute prior to start of study drug
  • Patients at very high risk for relapse post HCT as defined by very high disease risk index
  • Patients participating in a clinical trial where prevention of GVHD is the primary endpoint
  • Uncontrolled active infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis)
  • Patients who are pregnant
  • Patients on dialysis within 7 days of enrollment
  • Patients requiring ventilator support or oxygen supplementation exceeding 40% FiO2 within 14 days of enrollment.
  • Patients receiving agent within 30 days of enrollment. However, the Principal Investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of alpha-1-antitrypsin.
  • History of allergic reaction to alpha-1-antitrypsin
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    alpha-1-antitrypsin (AAT)

    16 doses of AAT through a catheter placed into a blood vessel over eight weeks.

    Drug: Alpha 1-Antitrypsin

Interventions

  • AAT will be given either in the hospital or the outpatient clinic two times per week.

    Also known as: AAT

06

What researchers measure

Primary outcomes

  1. Number of High Risk Patients Who Develop Steroid Refractory GVHD

    Number of High Risk patients who develop steroid refractory GVHD by day 100 post Hematopoietic cell transplant (HCT) . Steroid refractory GVHD defined as patients who did not achieve Complete Response (CR) or Partial Response (PR) by day 28 of systemic steroid treatment OR if additional immunosuppression beyond steroids was given for treatment of GVHD prior to 28 days of steroid treatment. * CR: All evaluable organs (skin, liver, GI tract) stage 0. For a response to be scored as CR on day 28, the patient must be in CR on that day and have had no intervening additional GVHD therapy. * PR: An improvement in one or more organ involved with GVHD symptoms without worsening in others. For a response to be scored as PR on day 28, the patient must be in PR on that day and have had no intervening additional GVHD therapy.

    Time frame: Day 100 post HCT.

Secondary outcomes

  1. Number of Participants Alive at 6 Months and 1 Year

    Overall survival - The number of that patients are still alive from the start of treatment at 6 months and 1 year

    Time frame: 6 months and 1 year

  2. Number of Participants With Non-relapse Mortality (NRM)

    Number of participants with NRM - deaths which could not be attributed to disease relapse or progression. Non-relapse mortality defined as death without prior relapse.

    Time frame: 6 months and 1 year

  3. Number of Participants With Relapse

    Number of participants with relapse at one year. Relapse defined as recurrence of disease that required transplant.

    Time frame: 1 year

  4. Number of Participants With Clinically Relevant GVHD States Grade II-IV GVHD

    Number of participants with clinically relevant GVHD states grade II-IV GVHD requiring systemic treatment. GVHD grades II-IV are defined as * Rash covering more than 50% of the body surface area, AND/OR * Total bilirubin \> 2 mg/dl AND/OR * Persistent nausea or vomiting, AND/OR * Diarrhea \> 500 ml/day AND/OR * Severe abdominal pain requiring treatment or blood present in the diarrhea

    Time frame: 100 days

  5. Number of Participants Achieving Overall Response

    For patients who develop GVHD prior to day 100 post-HCT, the number of participants achieving overall response. The overall response rate = complete remission and partial remission (CR + PR) 28 days after initiation of systemic steroid treatment.

    Time frame: Day 28

  6. Number of Participants With Severe GI GVHD Stage 3 or 4

    Number of participants with severe GI GVHD stage 3 or 4. GI GVHD stage 3 or 4 is defined as diarrhea \>1000 ml/day OR severe abdominal pain requiring treatment OR blood present in the diarrhea.

    Time frame: By day 100 post-HCT

  7. Number of Participants With Chronic GVHD Requiring Systemic Steroid Treatment

    Number of participants with chronic GVHD requiring systemic steroid treatment. Chronic GVHD Requiring Systemic Steroid Treatment: defined as the development of symptoms of chronic GVHD according to NIH Consensus Criteria that require treatment with oral or intravenous corticosteroids.

    Time frame: 1 year

  8. Number of Participants With Serious Infections

    Number of participants with serious infections (defined as grade 3 by the Blood and Marrow Transplant Clinical Trials Network). Serious Infection: Defined as bacterial, fungal, viral or parasitic infections that required oral or intravenous treatments such as antibiotics.

    Time frame: 1 year

07

Results

Posted May 24, 2021

Participant flow

Subjects were recruited and enrolled between August 2018 and July 2019.

Participant flow — Overall Study
MilestoneAlpha-1-antitrypsin (AAT)
Started30
Completed21
Not completed9
Withdrew: Death8
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of High Risk Patients Who Develop Steroid Refractory GVHD

Number of High Risk patients who develop steroid refractory GVHD by day 100 post Hematopoietic cell transplant (HCT) . Steroid refractory GVHD defined as patients who did not achieve Complete Response (CR) or Partial Response (PR) by day 28 of systemic steroid treatment OR if additional immunosuppression beyond steroids was given for treatment of GVHD prior to 28 days of steroid treatment. * CR: All evaluable organs (skin, liver, GI tract) stage 0. For a response to be scored as CR on day 28, the patient must be in CR on that day and have had no intervening additional GVHD therapy. * PR: An improvement in one or more organ involved with GVHD symptoms without worsening in others. For a response to be scored as PR on day 28, the patient must be in PR on that day and have had no intervening additional GVHD therapy.

Time frame:
Day 100 post HCT.
Reported as:
Count of participants · Participants
Number of High Risk Patients Who Develop Steroid Refractory GVHD
ParticipantsAlpha-1-antitrypsin (AAT)
Number of High Risk Patients Who Develop Steroid Refractory GVHD6
SecondaryNumber of Participants Alive at 6 Months and 1 Year

Overall survival - The number of that patients are still alive from the start of treatment at 6 months and 1 year

Time frame:
6 months and 1 year
Reported as:
Count of participants · Participants
Number of Participants Alive at 6 Months and 1 Year
ParticipantsAlpha-1-antitrypsin (AAT)
6 months26
1 year22
SecondaryNumber of Participants With Non-relapse Mortality (NRM)

Number of participants with NRM - deaths which could not be attributed to disease relapse or progression. Non-relapse mortality defined as death without prior relapse.

Time frame:
6 months and 1 year
Reported as:
Count of participants · Participants
Number of Participants With Non-relapse Mortality (NRM)
ParticipantsAlpha-1-antitrypsin (AAT)
6 months3
1 year6
SecondaryNumber of Participants With Relapse

Number of participants with relapse at one year. Relapse defined as recurrence of disease that required transplant.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Participants With Relapse
ParticipantsAlpha-1-antitrypsin (AAT)
Number of Participants With Relapse3
SecondaryNumber of Participants With Clinically Relevant GVHD States Grade II-IV GVHD

Number of participants with clinically relevant GVHD states grade II-IV GVHD requiring systemic treatment. GVHD grades II-IV are defined as * Rash covering more than 50% of the body surface area, AND/OR * Total bilirubin \> 2 mg/dl AND/OR * Persistent nausea or vomiting, AND/OR * Diarrhea \> 500 ml/day AND/OR * Severe abdominal pain requiring treatment or blood present in the diarrhea

Time frame:
100 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant GVHD States Grade II-IV GVHD
ParticipantsAlpha-1-antitrypsin (AAT)
Number of Participants With Clinically Relevant GVHD States Grade II-IV GVHD12
SecondaryNumber of Participants Achieving Overall Response

For patients who develop GVHD prior to day 100 post-HCT, the number of participants achieving overall response. The overall response rate = complete remission and partial remission (CR + PR) 28 days after initiation of systemic steroid treatment.

Time frame:
Day 28
Reported as:
Count of participants · Participants
Number of Participants Achieving Overall Response
ParticipantsAlpha-1-antitrypsin (AAT)
Number of Participants Achieving Overall Response10
SecondaryNumber of Participants With Severe GI GVHD Stage 3 or 4

Number of participants with severe GI GVHD stage 3 or 4. GI GVHD stage 3 or 4 is defined as diarrhea \>1000 ml/day OR severe abdominal pain requiring treatment OR blood present in the diarrhea.

Time frame:
By day 100 post-HCT
Reported as:
Count of participants · Participants
Number of Participants With Severe GI GVHD Stage 3 or 4
ParticipantsNumber of Participants Requiring Steroid Treatment
Number of Participants With Severe GI GVHD Stage 3 or 44
SecondaryNumber of Participants With Chronic GVHD Requiring Systemic Steroid Treatment

Number of participants with chronic GVHD requiring systemic steroid treatment. Chronic GVHD Requiring Systemic Steroid Treatment: defined as the development of symptoms of chronic GVHD according to NIH Consensus Criteria that require treatment with oral or intravenous corticosteroids.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Participants With Chronic GVHD Requiring Systemic Steroid Treatment
ParticipantsAlpha-1-antitrypsin (AAT)
Number of Participants With Chronic GVHD Requiring Systemic Steroid Treatment8
SecondaryNumber of Participants With Serious Infections

Number of participants with serious infections (defined as grade 3 by the Blood and Marrow Transplant Clinical Trials Network). Serious Infection: Defined as bacterial, fungal, viral or parasitic infections that required oral or intravenous treatments such as antibiotics.

Time frame:
1 year
Reported as:
Count of participants · Participants
Number of Participants With Serious Infections
ParticipantsAlpha-1-antitrypsin (AAT)
Number of Participants With Serious Infections2

Adverse events

Collected over up to 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1-antitrypsin (AAT)8/30 (26.7%)14/30 (46.7%)9/30 (30%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventAlpha-1-antitrypsin (AAT)
GVHDImmune system disorders4/30
Bronchopulmonary hemorrhage (DAH)Respiratory, thoracic and mediastinal disorders2/30
PneumonitisRespiratory, thoracic and mediastinal disorders2/30
Pulmonary EdemaRespiratory, thoracic and mediastinal disorders2/30
RelapseNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/30
Engraftment SyndromeGeneral disorders1/30
HeadacheNervous system disorders1/30
Line Infection: Gram negative Bacilli-CitrobacterInfections and infestations1/30
PneumoniaInfections and infestations1/30
Fungal Infection: Pneumocystis carinii pneumonia (PCP)Infections and infestations1/30
Most frequent other events
Showing 10 of 14
Most frequent other events
EventAlpha-1-antitrypsin (AAT)
Infusion ReactionInjury, poisoning and procedural complications5/30
Atrial FibrillationCardiac disorders1/30
Maculopapular rash with engraftment syndromeSkin and subcutaneous tissue disorders1/30
Oral mucositisGastrointestinal disorders1/30
Maculopapular RashSkin and subcutaneous tissue disorders1/30
HypertensionCardiac disorders1/30
KlebsiellaInfections and infestations1/30
PneumonitisRespiratory, thoracic and mediastinal disorders1/30
Generalized muscle weaknessGeneral disorders1/30
Pulmonary EdemaRespiratory, thoracic and mediastinal disorders1/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alpha-1-antitrypsin (AAT)
Median51 (20 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Alpha-1-antitrypsin (AAT)
Female11
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alpha-1-antitrypsin (AAT)
Hispanic or Latino4
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpha-1-antitrypsin (AAT)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White28
More than one race0
Unknown or Not Reported0
Diagnosis
Diagnosis(Participants)Alpha-1-antitrypsin (AAT)
Myelodysplastic syndrome13
Acute myelogenous leukemia9
Acute lymphoblastic leukemia5
Nonmalignant disease2
Non-Hodgkin's lymphoma1
Donor
Donor(Participants)Alpha-1-antitrypsin (AAT)
Matched related3
Matched unrelated26
Mismatched related0
Mismatched unrelated1
GVHD Prophylaxis
GVHD Prophylaxis(Participants)Alpha-1-antitrypsin (AAT)
CNI/MTX - calcineurin inhibitor/methotrexate14
CNI/MMF -Calcineurin inhibitors/mycophenolate mofetil0
calcineurin inhibitor/sirolimus15
Cyclophosphamide based0
Other1
08

Study locations

5 sites
  • City of Hope
    Duarte, California 91010, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
09

References and documents

Publications

  • Gergoudis SC, DeFilipp Z, Ozbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, Merli P, Morales G, Nakamura R, Reshef R, Rosler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with alpha-1-antitrypsin. Blood Adv. 2020 Dec 22;4(24):6098-6105. doi: 10.1182/bloodadvances.2020003336. PubMed 33351103 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Aug 2020, 24 months.

Results were first posted in May 2021, 9 months after primary completion.

Of 85 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 116. This study's 24 months is below that.

Counting every sponsor, half of 102 studies reached it within 51 months; a quarter within 29 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 8, 2018
StartActual
Aug 17, 2018
Primary completionActual
Aug 21, 2020
CompletionActual
Aug 21, 2020
Results first posted
May 24, 2021
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03459040
Lead sponsor
John Levine
Responsible party
John Levine (Professor of Internal Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Mar 8, 2018
Start date
Aug 17, 2018
Primary completion
Aug 21, 2020
Completion
Aug 21, 2020
Results posted
May 24, 2021
Last update
Jul 12, 2021

Study contacts

John Levine, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion